ArticleCell reports2026
Bidirectional control of vesicular GABA release, LTP, and amotivation by GluN2D-selective allosteric modulators and ketamine.
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
GABAergic inhibitory interneurons balance brain activity by suppressing excessive excitatory signaling and shaping network oscillations. Despite this critical function, our understanding of how neural circuits regulate GABAergic systems remains limited. Although N-methyl-D-aspartate receptor (NMDAR) functionality is defined by the GluN2A-D subunits, the interneuron NMDAR subunit composition remains unknown. Here, we show that GluN2D-NMDARs reside at presynaptic terminals of hippocampal parvalbumin-interneurons, and that the GluN2D intracellular C-terminal contains presynaptic targeting information. GluN2D-NMDARs are activated by changes in basal glutamate to bidirectionally control GABA release. Importantly, inhibition of GABA release by GluN2C/D modulators and subanesthetic ketamine is absent in mice lacking GluN2D in parvalbumin-interneurons, suggesting that GluN2D-dependent presynaptic regulation of GABA release may underlie some of ketamine's effects. The GluN2C/D-selective inhibitor NAB14 recapitulates durable ketamine-induced enhancement of long-term potentiation (LTP) and recovery of reward motivation in a behavioral model of depression without ketamine's undesirable effects, suggesting that GluN2D-NMDARs could be a therapeutically relevant target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.